(MedPage Today) — WASHINGTON — Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in more than 90% of patients who had refused cystectomy for high-risk disease, a small…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
